Akebia Therapeutics Inc(AKBA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:48 PM ET (Korea 10/28 08:48)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.11 | Insider Own | 2.71% | Shs Outstand | 271.7M | Perf Week | 6.84% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | -117.39% | Insider Trans | -0.74% | Shs Float | 269.6M | Perf Month | -26.06% |
| Enterprise Value | 0.24B | PEG | - | EPS next Q | -0.04 | Inst Own | 40.49% | Short Float | 8.56% | Perf Quarter | -47.59% |
| Income | -0.03B | P/S | 0.84 | EPS this Y | -600.58% | Inst Trans | 3.24% | Short Ratio | 3.05 | Perf Half Y | -53.49% |
| Sales | 0.22B | P/B | 7.17 | EPS next 5Y | - | ROA | -8.53% | Short Interest | 23.07M | Perf YTD | -58.98% |
| Book/sh | 0.09 | P/C | 1.16 | EPS past 3/5Y | 65.7% 62.4% | ROE | -109.38% | 52W High | -79.36% ($3.20) | Perf Year | -79.17% |
| Cash/sh | 0.57 | P/FCF | 4.55 | Sales past 3/5Y | -6.88% -4.37% | ROIC | -15.93% | 52W Low | 21.82% ($0.54) | Perf 3Y | -21.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.69% | Gross Margin | 78.92% | Volatility(W/M) | 10.8% 7.5% | Perf 5Y | -75.45% |
| Dividend TTM | - | EV/Sales | 1.08 | Sales Y/Y TTM | 7.52% | Oper. Margin | -6.02% | ATR (14) | 0.06 | Perf 10Y | -91.34% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | -3766.67% | Profit Margin | -13.54% | RSI (14) | 37.67 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.43 | Sales Q/Q | -21.36% | SMA20 | -11.23% ($0.74) | Beta | 0.21 | Target Price | $3.92 |
| Payout | - | Debt/Eq | 8.43 | Earnings | 2026/8/5 | SMA50 | -22.76% ($0.85) | Rel Volume | 0.72 | Prev Close | $0.64 |
| Employees | 194 | LT Debt/Eq | 6.44 | EPS/Sales Surpr. | 28.57% 0.56% | SMA200 | -42.9% ($1.16) | Avg Volume(3M) | 7.57M | Price | $0.66 |
| IPO | 2014/3/20 | Option/Short | Yes/Yes | Trades | 7052 | Volume | 5,427,994 | Change | 2.58% |
🩺 This is a US biopharmaceutical company specializing in kidney diseases, primarily focused on anemia treatments for patients with chronic kidney disease. The company has commercialized Vafseo (vadadustat), an oral anemia treatment for dialysis patients, and Auryxia (ferric citrate), a phosphate binder. It is a specialty and generic pharmaceutical company that is expanding its pipeline for rare kidney diseases.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
AKBA has weak earnings and a weak balance sheet
Of every $100 in sales, $6.02 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -600.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $84. Peers typically go for $197.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -75.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 40.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #51 of 83 in the industry
Based on market cap of $183M.
SIGA#49 SIGA Technologies Inc $230M PER - 
ADCT#50 Adc Therapeutics SA $203M PER - AKBA#51 Akebia Therapeutics Inc $183M PER - 
GLAS#52 Glass House Brands Inc $181M PER - 
DERM#53 Journey Medical Corp $140M PER - 
FAQ
What kind of company is AKBA?
AKBA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AKBA?
The market cap of AKBA is approximately $183M, ranking 4,081 within its sector.
What is the 52-week high and low for AKBA?
AKBA has recorded a 52-week high of $3.20 and a low of $0.54.
